Is	Be	VBZ	O	O	
fidaxomicin	fidaxomicin	NN	B-NP	O	
worth	worth	JJ	B-ADJP	O	
the	the	DT	B-NP	O	
cost	cost	NN	I-NP	O	
?	?	.	O	O	

An	An	DT	B-NP	O	
economic	economic	JJ	I-NP	O	
analysis	analysis	NN	I-NP	O	
.	.	.	O	O	

In	In	IN	B-PP	O	
May	May	NNP	B-NP	O	
2011	2011	CD	I-NP	O	
,	,	,	O	O	
the	the	DT	B-NP	O	
Food	Food	NNP	I-NP	O	
and	and	CC	I-NP	O	
Drug	Drug	NNP	I-NP	O	
Administration	Administration	NNP	I-NP	O	
approved	approve	VBD	B-VP	O	
fidaxomicin	fidaxomicin	NN	B-NP	O	
for	for	IN	B-PP	O	
the	the	DT	B-NP	O	
treatment	treatment	NN	I-NP	O	
of	of	IN	B-PP	O	
Clostridium difficile	Clostridium_difficile	JJ	B-NP	O	
infection	infection	NN	I-NP	O	
(	(	(	O	O	
CDI	CDI	NN	B-NP	B-protein	
)	)	)	O	O	
.	.	.	O	O	

It	It	PRP	B-NP	O	
has	have	VBZ	B-VP	O	
been	be	VBN	I-VP	O	
found	find	VBN	I-VP	O	
to	to	TO	I-VP	O	
be	be	VB	I-VP	O	
noninferior	noninferior	JJ	B-ADJP	O	
to	to	TO	B-PP	O	
vancomycin	vancomycin	NN	B-NP	O	
;	;	:	O	O	
however	however	RB	B-ADVP	O	
,	,	,	O	O	
its	its	PRP$	B-NP	O	
cost	cost	NN	I-NP	O	
-	-	HYPH	I-NP	O	
effectiveness	effectiveness	NN	I-NP	O	
for	for	IN	B-PP	O	
the	the	DT	B-NP	O	
treatment	treatment	NN	I-NP	O	
of	of	IN	B-PP	O	
CDI	CDI	NN	B-NP	B-protein	
remains	remain	VBZ	B-VP	O	
undetermined	undetermined	JJ	B-ADJP	O	
.	.	.	O	O	

We	We	PRP	B-NP	O	
developed	develop	VBD	B-VP	O	
a	a	DT	B-NP	O	
decision	decision	NN	I-NP	O	
analytic	analytic	JJ	I-NP	O	
simulation	simulation	NN	I-NP	O	
model	model	NN	I-NP	O	
to	to	TO	B-VP	O	
determine	determine	VB	I-VP	O	
the	the	DT	B-NP	O	
economic	economic	JJ	I-NP	O	
value	value	NN	I-NP	O	
of	of	IN	B-PP	O	
fidaxomicin	fidaxomicin	NN	B-NP	O	
for	for	IN	B-PP	O	
CDI	CDI	NN	B-NP	B-protein	
treatment	treatment	NN	I-NP	O	
from	from	IN	B-PP	O	
the	the	DT	B-NP	O	
third	third	JJ	I-NP	O	
-	-	HYPH	I-NP	O	
party	party	NN	I-NP	O	
payer	payer	NN	I-NP	O	
perspective	perspective	NN	I-NP	O	
.	.	.	O	O	

We	We	PRP	B-NP	O	
looked	look	VBD	B-VP	O	
at	at	IN	B-PP	O	
CDI	CDI	NNP	B-NP	O	
treatment	treatment	NN	I-NP	O	
in	in	IN	B-PP	O	
these	these	DT	B-NP	O	
3	3	CD	I-NP	O	
cases	case	NNS	I-NP	O	
:	:	:	O	O	
(	(	(	B-LST	O	
1	1	LS	I-LST	O	
)	)	)	O	O	
no	no	DT	B-NP	O	
fidaxomicin	fidaxomicin	NN	I-NP	O	
,	,	,	O	O	
(	(	(	B-LST	O	
2	2	LS	I-LST	O	
)	)	)	O	O	
only	only	RB	B-NP	O	
fidaxomicin	fidaxomicin	NN	I-NP	O	
,	,	,	O	O	
and	and	CC	O	O	
(	(	(	B-LST	O	
3	3	LS	I-LST	O	
)	)	)	O	O	
fidaxomicin	fidaxomicin	NN	B-NP	O	
based	base	VBN	B-VP	O	
on	on	IN	B-PP	O	
strain	strain	NN	B-NP	O	
typing	typing	NN	I-NP	O	
results	result	NNS	I-NP	O	
.	.	.	O	O	

The	The	DT	B-NP	O	
incremental	incremental	JJ	I-NP	O	
cost	cost	NN	I-NP	O	
-	-	HYPH	B-NP	O	
effectiveness	effectiveness	NN	I-NP	O	
ratio	ratio	NN	I-NP	O	
for	for	IN	B-PP	O	
fidaxomicin	fidaxomicin	NN	B-NP	O	
based	base	VBN	B-VP	O	
on	on	IN	B-PP	O	
screening	screen	VBG	B-VP	O	
given	give	VBN	B-PP	O	
current	current	JJ	B-NP	O	
conditions	condition	NNS	I-NP	O	
was	be	VBD	B-VP	O	
>$	>$	$	B-NP	O	
43.7	43.7	CD	I-NP	O	
million	million	CD	I-NP	O	
per	per	IN	B-PP	O	
quality	quality	NN	B-NP	O	
-	-	HYPH	O	O	
adjusted	adjust	VBN	B-NP	O	
life	life	NN	I-NP	O	
-	-	HYPH	B-NP	O	
year	year	NN	I-NP	O	
and	and	CC	O	O	
using	use	VBG	B-VP	O	
only	only	RB	B-NP	O	
fidaxomicin	fidaxomicin	NN	I-NP	O	
was	be	VBD	B-VP	O	
dominated	dominate	VBN	I-VP	O	
(	(	(	O	O	
ie	ie	FW	O	O	
,	,	,	O	O	
more	more	RBR	B-ADJP	O	
costly	costly	JJ	I-ADJP	O	
and	and	CC	O	O	
less	less	RBR	B-ADJP	O	
effective	effective	JJ	I-ADJP	O	
)	)	)	O	O	
by	by	IN	B-PP	O	
the	the	DT	B-NP	O	
other	other	JJ	I-NP	O	
2	2	CD	I-NP	O	
treatment	treatment	NN	I-NP	O	
strategies	strategy	NNS	I-NP	O	
explored	explore	VBN	B-VP	O	
.	.	.	O	O	

The	The	DT	B-NP	O	
fidaxomicin	fidaxomicin	NN	I-NP	O	
strategy	strategy	NN	I-NP	O	
tended	tend	VBD	B-VP	O	
to	to	TO	I-VP	O	
remain	remain	VB	I-VP	O	
dominated	dominated	JJ	B-ADJP	O	
,	,	,	O	O	
even	even	RB	B-ADVP	O	
at	at	IN	B-PP	O	
lower	low	JJR	B-NP	O	
costs	cost	NNS	I-NP	O	
.	.	.	O	O	

With	With	IN	B-PP	O	
approximately	approximately	RB	B-NP	O	
50%	50%	CD	I-NP	O	
of	of	IN	B-PP	O	
CDI	CDI	NN	B-NP	B-protein	
due	due	JJ	B-ADJP	O	
to	to	TO	B-PP	O	
the	the	DT	B-NP	O	
NAP1	NAP1	NN	I-NP	B-protein	
/	/	SYM	B-NP	O	
BI	BI	NN	I-NP	O	
/	/	SYM	O	O	
027	027	CD	B-NP	O	
strain	strain	NN	I-NP	O	
,	,	,	O	O	
a	a	DT	B-NP	O	
course	course	NN	I-NP	O	
of	of	IN	B-PP	O	
fidaxomicin	fidaxomicin	NN	B-NP	O	
would	would	MD	B-VP	O	
need	need	VB	I-VP	O	
to	to	TO	I-VP	O	
cost	cost	VB	I-VP	O	
≤$150	≤$150	CD	B-NP	O	
to	to	TO	B-VP	O	
be	be	VB	I-VP	O	
cost	cost	AFX	B-ADJP	O	
-	-	HYPH	I-ADJP	O	
effective	effective	JJ	B-ADJP	O	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
treatment	treatment	NN	I-NP	O	
of	of	IN	B-PP	O	
all	all	DT	B-NP	O	
CDI	CDI	NNP	I-NP	O	
cases	case	NNS	I-NP	O	
and	and	CC	O	O	
between	between	IN	B-PP	O	
$160	$160	CD	B-NP	O	
and	and	CC	I-NP	O	
$400	$400	CD	I-NP	O	
to	to	TO	B-VP	O	
be	be	VB	I-VP	O	
cost	cost	AFX	B-ADJP	O	
-	-	HYPH	I-ADJP	O	
effective	effective	JJ	B-ADJP	O	
for	for	IN	B-PP	O	
those	those	DT	B-NP	O	
with	with	IN	B-PP	O	
a	a	DT	B-NP	O	
non-NAP1	non-NAP1	NN	I-NP	O	
/	/	SYM	B-NP	O	
BI	BI	NN	I-NP	O	
/	/	SYM	O	O	
027	027	CD	B-NP	O	
strain	strain	NN	I-NP	O	
(	(	(	O	O	
ie	ie	FW	B-NP	O	
,	,	,	O	O	
treatment	treatment	NN	B-NP	O	
based	base	VBN	B-VP	O	
on	on	IN	B-PP	O	
strain	strain	NN	B-NP	O	
typing	typing	NN	I-NP	O	
)	)	)	O	O	
.	.	.	O	O	

Given	Give	VBN	B-PP	O	
the	the	DT	B-NP	O	
current	current	JJ	I-NP	O	
cost	cost	NN	I-NP	O	
and	and	CC	I-NP	O	
NAP1	NAP1	NN	I-NP	B-protein	
/	/	SYM	B-NP	O	
BI	BI	NN	I-NP	O	
/	/	SYM	O	O	
027	027	CD	B-NP	O	
accounting	accounting	NN	I-NP	O	
for	for	IN	B-PP	O	
approximately	approximately	RB	B-NP	O	
50%	50%	CD	I-NP	O	
of	of	IN	B-PP	O	
isolates	isolate	NNS	B-NP	O	
,	,	,	O	O	
using	use	VBG	B-VP	O	
fidaxomicin	fidaxomicin	NN	B-NP	O	
as	as	IN	B-PP	O	
a	a	DT	B-NP	O	
first	first	JJ	I-NP	O	
-	-	HYPH	I-NP	O	
line	line	NN	I-NP	O	
treatment	treatment	NN	I-NP	O	
for	for	IN	B-PP	O	
CDI	CDI	NNP	B-NP	O	
is	be	VBZ	B-VP	O	
not	not	RB	O	O	
cost	cost	NN	B-NP	O	
-	-	HYPH	B-VP	O	
effective	effective	JJ	B-ADJP	O	
.	.	.	O	O	

However	However	RB	B-ADVP	O	
,	,	,	O	O	
typing	typing	NN	B-NP	O	
and	and	CC	I-NP	O	
treatment	treatment	NN	I-NP	O	
with	with	IN	B-PP	O	
fidaxomicin	fidaxomicin	NN	B-NP	O	
based	base	VBN	B-VP	O	
on	on	IN	B-PP	O	
strain	strain	NN	B-NP	O	
may	may	MD	B-VP	O	
be	be	VB	I-VP	O	
more	more	RBR	B-ADJP	O	
promising	promising	JJ	I-ADJP	O	
depending	depend	VBG	B-PP	O	
on	on	IN	B-PP	O	
the	the	DT	B-NP	O	
costs	cost	NNS	I-NP	O	
of	of	IN	B-PP	O	
fidaxomicin	fidaxomicin	NN	B-NP	O	
.	.	.	O	O	

